Tal Behar’s Post

𝐍𝐚𝐯𝐢𝐠𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐚𝐧𝐝 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐨𝐫 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟎 Solid tumors are #heterotypic collections of a variety of cell types, including cancer cells, cancer stem cells, connective-tissue cells, and #immune cells. For malignant solid tumors, surgery is currently the most appropriate therapeutic choice. Chemotherapy is usually used with other solid tumor treatments such as surgery and radiation. #Solidtumor therapies are #pharmaceuticals used to treat tumors including #lungcancer, #breastcancer, prostate cancer, colorectal cancer, cervical cancer, and others. Solid tumor therapeutics are continuing to lead the way in #oncology treatments as an effective anti-cancer therapy in the global oncology therapeutics. The Solid Tumor Testing Market size was valued at USD 40.73 Billion in 2023 and the total Solid Tumor Testing revenue is expected to grow at a CAGR of 7.85% from 2024 to 2030, reaching nearly USD 69.13 Billion. 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞: https://lnkd.in/gk2s9Bj6 𝗦𝗶𝘁𝗲 𝗼𝗳 𝗢𝗿𝗶𝗴𝗶𝗻 -Prostrate Cancer -Ovarian Cancer -Bladder Cancer -Pancreatic Cancer -Others Most often for solid tumors, that's a mix of #chemotherapy, #radiation #therapy and #surgery. Your child's team may include these solid tumor team members. Medical #oncologists are cancer doctors. They are experts in using chemotherapy “#chemo” and other #medicines to treat #cancer. Some types of solid tumors may be difficult to diagnose by morphology because of an ambiguous appearance or failure to show discernible features of specific differentiation. Examples of tumors in which cytogenetic analysis is particularly useful in resolving this type of diagnostic problem include small round cell tumors of childhood and spindle cell tumors. Round cell tumors of childhood include lymphoma, neuroblastoma, Ewing's sarcoma/peripheral neuroepithelioma, embryonal rhabdomyosarcoma, and alveolar rhabdomyosarcoma. Lymphoma can usually be excluded from the differential diagnosis by using clinical data and immunohistochemistry. Although peripheral neuroectodermal tumors are similar to neuroblastomas, a number of #biological and #molecular features suggest that they are also related to Ewing's sarcoma. Both have the same translocation [t(11;22)(q24;q11-12)] and express MYC and neither expresses MYCN. While immunohistochemistry or electron microscopy of the round cell tumors is useful, in a significant proportion of cases the final diagnosis is uncertain even after morphologic approaches have been exhausted. Specific diagnosis is not trivial, since prognosis and therapy differ for each one of these tumors. Hologic, Inc. Genesis Healthcare System Jazz Pharmaceuticals Sino Biopharmaceutical Limited Incyte ONO PHARMA USA Athena Behavioral Health Octapharma Ipsen Chiesi Group SHIMADZU CORPORATION Hengrui Pharma Co.,Ltd AdaptHealth Dexcom

In a breakthrough that could transform how prostate cancer is diagnosed, researchers at Massachusetts Institute of Technology and partner institutions have developed a novel #artificialintelligence system that mimics how dogs smell #cancer. The research, published this week, shows promise in creating a more reliable and less invasive screening tool for one of the most common cancers affecting men worldwide. The team, led by researchers at MIT's Media Lab, tackled a persistent challenge in #medicaldiagnostics: creating a reliable way to detect #prostatecancer through #urineanalysis. While trained dogs have shown remarkable accuracy in sniffing out prostate cancer, replicating this ability in a #medicaldevice has proven difficult. The new approach moves away from traditional methods of identifying specific molecules and instead focuses on detecting overall "#scentpatterns" - similar to how a dog's nose works. "We're not trying to identify individual molecules anymore," explains Dr. Andreas Mershin, the study's senior author. "Instead, we're looking at the entire 'smell picture' of the sample, just as a dog would." This novel approach uses advanced machine learning techniques borrowed from image recognition technology, treating the chemical signatures from urine samples as if they were images to be analyzed. The research team worked with 365 urine samples from patients across four major medical centers in the United States. A key innovation was their development of sophisticated algorithms to remove hospital-specific biases from the data - a common problem in #medicalAI that can lead to misleading results. While this reduced the system's apparent accuracy from 81% to 75%, the researchers believe the lower number represents a more realistic and reliable performance level. Prostate cancer, which is expected to affect 2.9 million men annually by 2040, currently relies on a combination of PSA blood tests and digital rectal examinations for initial detection, followed by invasive biopsies for confirmation. These methods can lead to both false positives and missed diagnoses. The new technology, if successfully developed into a clinical tool, could provide a non-invasive screening method that helps doctors make more informed decisions about when to proceed with biopsies. The research team is now focusing on understanding the biological mechanisms behind cancer detection, particularly studying specific receptors that are overexpressed in prostate cancer tissue. "This work represents a significant step toward creating more reliable, non-invasive diagnostic tools," says Mershin. "By better understanding how both dogs and machines can detect cancer through smell, we're opening up new possibilities for early detection and monitoring of this disease."

Celebrating Excellence in #Oncology The field of oncology is driven forward by extraordinary individuals who dedicate their lives to advancing cancer research, treatment, and patient care. Today, we honor 10 world-renowned oncologists whose work has transformed the landscape of cancer medicine: 1️⃣ Dr. Jason Westin – A visionary leader in lymphoma clinical research, Dr. Westin is the Section Chief of Aggressive and Indolent Lymphomas at MD Anderson Cancer Center, Houston. His work shapes the future of lymphoma treatment. 2️⃣ Dr. Caroline Robert – A global authority in melanoma research, Dr. Robert’s groundbreaking advancements in immunotherapy and targeted therapies have redefined treatment standards for skin cancers. 3️⃣ Dr.Beth Karlan – Known for her impactful ovarian cancer research, Dr. Karlan’s contributions have transformed gynecologic oncology. She has also served on the National Cancer Advisory Board. 4️⃣ Dr. Steven T. Rosen – A leader in hematologic malignancies, Dr. Rosen’s work at City of Hope has been instrumental in advancing cancer research and patient care. 5️⃣ Dr.James Abbruzzese – A pioneer in pancreatic cancer research, Dr. Abbruzzese’s efforts have significantly advanced gastrointestinal oncology at Duke University. 6️⃣ Dr. Theodore M. Ross – A colorectal surgery expert at Cleveland Clinic Canada, Dr. Ross specializes in digestive diseases, combining clinical and research excellence. 7️⃣ Dr.Rachel Dultz – A breast cancer surgery specialist with over 27 years of experience, Dr. Dultz has dedicated her career to improving breast health and patient outcomes. 8️⃣ Dr. Christopher Wolfgang – Director of Hepatobiliary & Pancreatic Surgery at NYU Langone Health, Dr. Wolfgang has performed over 1,200 pancreatic surgeries, setting a global benchmark for pancreatic cancer treatment. 9️⃣ Dr. Eric Winer, MD, FASCO – A leading figure in breast cancer care and research, Dr. Winer’s contributions have transformed breast cancer treatment protocols worldwide. 🔟 Dr. George Somlo – Known for his expertise in breast cancer, Dr. Somlo’s research and clinical work at City of Hope have significantly advanced oncology practice. These experts inspire us with their dedication, knowledge, and groundbreaking contributions to cancer care. Let's celebrate their achievements and continue to support the global fight against cancer. Who inspires you in the field of oncology? Share your thoughts in the comments! 💬 #OncologyFrontier #CancerResearch #OncologyLeaders #Lymphoma #Melanoma #BreastCancer #PancreaticCancer #CancerCare #Immunotherapy #TargetedTherapies #GynecologicOncology #ColorectalCancer #Hematology #OncologyInnovation #CancerTreatment #OncologyInsights #PrecisionMedicine #CancerAwareness #OncologyCommunity

Our friends at the University of California, Davis continue to innovate in the fight against lung cancer. Led by Chinh Phan, DO, DAABIP, UC Davis Health has introduced two new technologies that provide advanced imaging for lung cancer diagnosis and treatment. The first is a state-of-the-art mobile 3D CT imaging system that can detect potentially cancerous growths for more precise lung cancer biopsies. This technology is particularly significant because it can catch lung cancer at an earlier stage, when it is more treatable. The system pairs the Cios Spin, made by Siemens Healthineers, with a robotic-assisted bronchoscopy system called the Ion, made by Intuitive. The synergy of these two systems improves the precision and accuracy of lung nodule biopsies, enabling safer and earlier diagnosis of lung cancer. The second technology tracks the progress of lung cancer treatment. This real-time visualization means shorter procedures, improved accuracy, and safer biopsies. After a year of using the Cios Spin and Ion together, the team at UC Davis Health has seen a major shift in lung cancer detection. These advancements are a testament to the power of technology in transforming healthcare. They bring hope to people with lung cancer and their families, and they underscore the importance of continued investment in medical research and innovation. Let’s spread the word about this incredible breakthrough and the hope it brings to those battling lung cancer. #LungCancer #MedicalInnovation #HealthcareTechnology https://lnkd.in/g-zR3QR4

We are proud to announce our backing of two ground-breaking breast cancer research projects, kicking off our commitment to £1 million of vital research over the next five years. The projects will enable better understanding of the disease from early diagnosis to treatment of secondary breast cancer, when the disease has spread and is treatable but no longer curable. One of the research projects is with Prof Charles Swanton, supporting his work studying metastatic triple negative breast cancer at the world-famous Francis Crick Institute. The project is a collaboration between the Francis Crick Institute, UCL (London), UNICANCER (Paris), Institut Curie (Paris) and Gustave Roussy (Villejuif.) It will help transform the understanding of cancer evolution and help develop practical steps towards an era of precision medicine. Future Dreams trustee and consultant medical oncologist, Dr Fharat Raja said: “It is incredibly exciting to be supporting this immensely important work that enhances our understanding of the evolution of cancer which will eventually allow us to exploit the findings within the tumours for better treatments." Running alongside this project, Future Dreams is also funding a PhD student at University of Cambridge to understand if AI screening could identify women who are more at risk of developing breast cancer. Prof Fiona Gilbert, from the Radiology department of University of Cambridge stated: “We are thrilled that Future Dreams is funding a PhD studentship and some senior clinical research time. The purpose of the grant is to assess different artificial intelligence tools which use information from mammograms to predict which women will develop breast cancer over the next five years. This important work will help inform the UK screening programme on whether AI tools are ready to be adopted into clinical practice." Future Dreams trustee and consultant breast and oncoplastic surgeon, Joanna Franks, said: “Being able to use AI in breast screening will be a tremendous breakthrough enabling quicker assessments, earlier diagnosis and help all women including those who are at greater risk of developing breast cancer. It will transform the UK screening programme." To read more about our commitment to vital research, click the link. https://bit.ly/4euamCX #futuredreams #breastcancer #breastcancerresearch #triplenegativebc #triplenegativebreastcancer #researchproject #franciscrick #breastcancerscreening #artificialintelligence

Advancing Breast Cancer Detection | Transpara at Johns Hopkins - DistilINFO Hospital IT #TransparaAtJohnsHopkins: Johns Hopkins Hospital is advancing breast cancer detection with Transpara, a cutting-edge technology that improves accuracy and efficiency in mammography screenings. #BenefitsOfTranspara: Transpara offers numerous benefits, including increased detection rates, reduced false positives, and improved overall patient outcomes. #HowTransparaWorks: Transpara utilizes artificial intelligence to analyze mammograms, providing radiologists with additional information to make more informed decisions. #ClinicalStudyResults: Clinical studies have shown that Transpara significantly improves the accuracy of mammography readings, leading to earlier detection of breast cancer. #ImplementationAtJohnsHopkins: Johns Hopkins Hospital has successfully implemented Transpara into their breast cancer screening program, enhancing the quality of care for their patients ai.mediformatica.com #cancer #transpara #johnshopkins #breastcancer #medical #imaging #radiologist #technology #johnshopkinsmedicine #medicine #radiologists #this #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3TgWWAc)

In a preliminary clinical trial for patients with #Glioblastoma (GBM), one of the most aggressive forms of brain cancer, researchers Marcela Maus, MD, PhD, Bryan Choi, MD, PhD, and colleagues have witnessed a rapid and dramatic decrease in patient tumor size after a single injection of a next-generation CAR-T cell therapy. CAR-T therapy works by using a patient's own cells to fight cancer. A patient's cells are extracted, modified to produce proteins on their surface called chimeric antigen receptors (CAR), and then injected back into the body to target the tumor directly. However, for this study, the team used a next-generation CAR-T cell therapy called CAR-TEAM, that takes into account tumor differences in patients as well, because they have a dual targeting mechanism that enables them to attack the cancer cells at two different targets. This study was a preliminary clinical trial, involving only three patients. While all three patients showed rapid tumor regression after a single injection, the team did note they observed eventual tumor progression in all the cases, though in one case, there was no progression for over six months. “Our work to date shows signs that we are making progress, but there is more to do,” said co-author Elizabeth Gerstner, MD, a neuro-oncologist in the Department of Neurology at Massachusetts General Hospital. Read the full story: https://buff.ly/3Tk7D5a #cureforcancer #cancertherapy #CARTcells #cancertreatment #GBM #glioblastoma #cancer 

A research team from UH Seidman Cancer Center and Case Western Reserve University School of Medicine has received a prestigious grant from the National Institutes of Health to help develop better treatment options for metastatic colorectal cancer. Co-investigator Joseph Willis, MD, Vice Chairman of Translational Research, Pathology, at UH Cleveland Medical Center, is collaborating with fellow principal investigator Rui Wang, PhD, Assistant Professor of Surgery at Case Western Reserve University and UH Cleveland Medical Center, and co-investigator Zhenghe "John" Wang, PhD, Co-Leader of Case Comprehensive Cancer Center’s Cancer Genomics and Epigenomics Program. Together they’re working to understand how endothelial cells in the liver – the organ where over 80 percent of colorectal cancer metastasis occurs – might promote the development of metastatic disease. Already, they have some answers. Early experimental results show that liver epithelial cells activate a surface protein called HER3 in cancer cells, inducing growth of metastatic colorectal cancer in the liver. But the team is finding that this process occurs in a somewhat unique way. “We made the paradigm-shifting discovery that the protein LRG1 secreted from liver epithelial cells is a novel HER3 ligand that activates colorectal cancer-associated HER3 and promotes colorectal cancer cell growth,” Dr. Rui Wang says. “We also have preliminary data to show that when you block this LRG1 and HER3 mechanism, the tumors in the liver actually grow much more slowly.” “We will use the patient-derived specimens in collaboration with UH Cleveland Medical Center to determine whether the newly discovered LRG1-HER3 pathway exists in human pathological conditions,” Dr. Willis says. “As a result, our findings will help us to understand how this novel pathway affects cancer development in humans and how it harms patient outcomes.” Read more at https://lnkd.in/gHvbENdk #cancerresearch #colorectalcancer #NIH #physicianexcellence #patientsfirst

This week's headline article shifts the Pathology News spotlight onto neoadjuvant therapy and the use of computational methods to enhance personalized medicine. In a new study, researchers at the Radboud University Medical Center (RUMC) and the The Netherlands Cancer Institute (NKI) proposed computational biomarkers based on deep learning to predict pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer, using only routine H&E-stained biopsy slides. This approach could significantly enhance the personalization of treatment for breast cancer patients by identifying those likely to benefit from chemotherapy, thereby avoiding unnecessary treatment for non-responders. Key highlights from the study include: 👉 The development of computational methods to analyze the tumor microenvironment, identifying robust biomarkers such as tumor-infiltrating lymphocytes (TILs) and cell division rates. 👉 The predictive value of these biomarkers in assessing the likelihood of a patient achieving pCR to neoadjuvant chemotherapy. 👉 A special focus on the low rates of pCR in patients with triple-negative and luminal B breast cancer, underscoring the need for better predictive tools in these subgroups. 👉 Initial results show promising predictive performance of these biomarkers, with the potential to spare non-responders from the adverse effects of unnecessary chemotherapy. #digitalpathology #pathologynews